EXHIBIT 29

Case 3:16-md-P27711-nYG-a Pocument 27552-30 t Filest 01/25/19: Page 2-064

```
1
              UNITED STATES DISTRICT COURT
2
             NORTHERN DISTRICT OF CALIFORNIA
3
   ----X
4 IN RE: ROUNDUP PRODUCTS ) MDL No. 2741
5 LIABILITY LITIGATION
                              ) Case No.
6
                 _____) 16-md-02741-VC
7
    THIS DOCUMENT RELATES TO ALL )
8
   CASES
9
                              )
10
11
   CONFIDENTIAL - SUBJECT TO PROTECTIVE ORDER
12
13
14 VIDEOTAPED DEPOSITION OF MARK A. MARTENS, Ph.D.
15
                    WASHINGTON, D.C.
                 FRIDAY, APRIL 7, 2017
16
17
                      9:23 A.M.
18
19
20
21
22
23
24
25 Reported by: Leslie A. Todd
```

- 1 and to see where exactly that we -- both parties
- 2 could understand what's actually going on, and
- 3 whether we have an initiation of oxidative damage and
- 4 whether possible genotoxicity was secondary to the
- 5 initiation of oxidative damage.
- 6 Q Okay. And I assume by the same token,
- 7 you never shared -- Monsanto never shared the Parry
- 8 reports with any regulatory agency.
- 9 A That was not -- that was internal, you
- 10 know, expert to our company, you know, information,
- and exchange of views, which had as the only
- 12 objective to inspire Monsanto to do some
- 13 supplementary research and to better understand the
- 14 effects that have been published by Peluso and
- 15 Bolognesi.
- MS. WAGSTAFF: Okay. Strike as
- 17 nonresponsive.
- 18 BY MS. WAGSTAFF:
- 19 Q My question was, I assume by the same
- token that Monsanto never shared the Parry report
- 21 with any regulatory agencies, correct?
- 22 A That's correct.
- MR. GRIFFIS: The answer was responsive.
- THE WITNESS: Yeah.
- 25 BY MS. WAGSTAFF:

```
And that's the -- MON 35050 is also the
 1
           0
 2.
     formulation used in the Peluso and the -- the --
 3
                Bolognesi.
           Α
 4
           0
                -- Bolognesi paper.
 5
           Α
                Yes.
                Right?
 6
           Q
           Α
 7
                Yes.
 8
           0
                Okay. And it says: "The in vivo
     genotoxicity finding was cause of concern to
 9
10
     regulatory authorities."
11
                Correct?
12
           Α
                Yes.
13
                Okay. So now these are your thoughts
14
     that the genotoxicity finding in vivo was of concern,
15
     correct?
16
           Α
                Yes.
17
                Okay. And this is -- then you're --
           0
18
    you're going on to educate these people who are
19
     listening to your presentation about the toxicity of
20
     surfactants, and you said: "To better understand the
21
     significance, Monsanto undertook research to examine
22
     the role of intraperitoneal versus oral, DMSO olive
    oil versus saline, and then the Italian formulation
23
    with and without glyphosate." Right?
24
25
                Yes, exactly.
           Α
```